<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601001</url>
  </required_header>
  <id_info>
    <org_study_id>20150134</org_study_id>
    <nct_id>NCT02601001</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults</brief_title>
  <official_title>A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability&#xD;
      of omecamtiv mecarbil in healthy volunteers in Japan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due&#xD;
      to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021&#xD;
      and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics,&#xD;
      Cytokinetics is now listed as the sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2015</start_date>
  <completion_date type="Actual">January 6, 2016</completion_date>
  <primary_completion_date type="Actual">January 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</measure>
    <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</measure>
    <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1</measure>
    <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration</measure>
    <time_frame>Day 8 predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 1: Accumulation Ratio</measure>
    <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
    <description>Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</measure>
    <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</measure>
    <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2</measure>
    <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration</measure>
    <time_frame>Day 27 predose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosing Period 2: Accumulation Ratio</measure>
    <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
    <description>Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>35 days</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment.&#xD;
A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:&#xD;
fatal&#xD;
life threatening&#xD;
required in patient hospitalization or prolongation of existing hospitalization&#xD;
resulted in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Laboratory Toxicities</measure>
    <time_frame>35 days</time_frame>
    <description>Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline:&#xD;
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.&#xD;
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL).&#xD;
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.&#xD;
Grade 4: Life-threatening consequences; urgent intervention indicated.&#xD;
Grade 5: Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1</measure>
    <time_frame>Day 1 predose and day 8</time_frame>
    <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG).&#xD;
Maximum increase from Period 1 baseline was categorized as:&#xD;
≤ 30 milliseconds (ms) &gt; 30 to 60 ms &gt; 60 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2</measure>
    <time_frame>Day 20 predose and Day 27</time_frame>
    <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG.&#xD;
Maximum increase from Period 2 baseline was categorized as:&#xD;
≤ 30 ms &gt; 30 to 60 ms &gt; 60 ms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omecamtiv mecarbil 25 mg / 37.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was &lt; 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omecamtiv mecarbil 25 mg / 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was &lt; 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omecamtiv mecarbil</intervention_name>
    <description>Omecamtiv mecarbil tablets for oral administration</description>
    <arm_group_label>Omecamtiv mecarbil 25 mg / 37.5 mg</arm_group_label>
    <arm_group_label>Omecamtiv mecarbil 25 mg / 50 mg</arm_group_label>
    <other_name>AMG 423</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No history or evidence of clinically relevant medical disorders as determined by the&#xD;
             Investigator, and in good health as determined by a pre-study physical examination and&#xD;
             medical history with no clinically significant abnormalities, normal vital signs and&#xD;
             no history or presence of a clinically significant abnormal electrocardiogram finding&#xD;
&#xD;
          -  Subjects' pre-study clinical laboratory findings (including creatine phosphokinase)&#xD;
             should be within normal range or if outside of the normal range, are deemed not&#xD;
             clinically significant by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically significant disorder/disease, including gastro intestinal abnormalities&#xD;
             that might interfere with absorption&#xD;
&#xD;
          -  An unstable medical condition, defined as having been hospitalized within 28 days&#xD;
             before day 1, major surgery within 6 months before day 1, or otherwise unstable in the&#xD;
             judgment of the Investigator&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition, or&#xD;
             disease that, in the opinion of the Investigator or Medical Monitor would pose a risk&#xD;
             to subject safety or interfere with the study evaluation, procedures, or completion&#xD;
&#xD;
          -  History of malignancy of any type other than surgically excised non-melanomatous skin&#xD;
             cancers or in situ cervical cancer within 5 years before the day of dosing&#xD;
&#xD;
          -  Use of any prescription or over-the-counter medications within 14 days or 5 half-lives&#xD;
             (whichever time period is greater), prior to receiving the first dose of omecamtiv&#xD;
             mecarbil (acetaminophen up to 2 grams per day for analgesia and hormone replacement&#xD;
             therapy (e.g., estrogen) will be allowed&#xD;
&#xD;
          -  Use of any known inhibitors of CYP3A4/p-glycoprotein (P-gp) or CYP2D6 within 14 days&#xD;
             or 5 half-lives, whichever is longer; or use of grapefruit juice or grapefruit&#xD;
             containing products within 7 days prior to receiving the first dose of omecamtiv&#xD;
             mecarbil&#xD;
&#xD;
          -  Use of any known CYP3A4 inducers within 30 days or 5 half-lives, whichever is longer,&#xD;
             before receiving omecamtiv mecarbil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>April 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single center in Japan. Participants were enrolled from 13 November 2015 to 24 November 2015.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to one of three treatment groups in a 1:2:2 ratio.&#xD;
The study consisted of a screening period, two 8-day treatment periods with an 11-day drug holiday in between, and an end of study (EOS) visit on day 35.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
        </group>
        <group group_id="P2">
          <title>Period 1 Group A: Omecamtiv Mecarbil 25 mg</title>
          <description>Participants received omecamtiv mecarbil (OM) 25 mg BID in dosing period 1 (days 1 to 8).</description>
        </group>
        <group group_id="P3">
          <title>Period 1 Group B: Omecamtiv Mecarbil 25 mg</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
        </group>
        <group group_id="P4">
          <title>Period 2 Group A: Omecamtiv Mecarbil 25 mg</title>
          <description>Participants who received omecamtiv mecarbil 25 mg BID in dosing period 1 then received omecamtiv mecarbil 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose).</description>
        </group>
        <group group_id="P5">
          <title>Period 2 Group A: Omecamtiv Mecarbil 37.5 mg</title>
          <description>Participants who received omecamtiv mecarbil 25 mg BID in dosing period 1 then received omecamtiv mecarbil 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
        <group group_id="P6">
          <title>Period 2 Group B: Omecamtiv Mecarbil 25 mg</title>
          <description>Participants who received omecamtiv mecarbil 25 mg BID in dosing period 1 then received omecamtiv mecarbil 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
        <group group_id="P7">
          <title>Period 2 Group B: Omecamtiv Mecarbil 50 mg</title>
          <description>Participants who received omecamtiv mecarbil 25 mg BID in dosing period 1 then received omecamtiv mecarbil 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dosing Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dosing Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
        </group>
        <group group_id="B2">
          <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was &lt; 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL participants continued to receive 25 mg BID.</description>
        </group>
        <group group_id="B3">
          <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was &lt; 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL participants continued to receive 25 mg BID.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="4.2"/>
                    <measurement group_id="B2" value="35.5" spread="7.6"/>
                    <measurement group_id="B3" value="27.3" spread="4.6"/>
                    <measurement group_id="B4" value="31.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
        <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
        <population>The pharmacokinetic (PK) analysis set included all randomized participants who received at least 1 dose of omecamtiv mecarbil and had at least 1 evaluable omecamtiv mecarbil PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
          <group group_id="O2">
            <title>Group B: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
          <population>The pharmacokinetic (PK) analysis set included all randomized participants who received at least 1 dose of omecamtiv mecarbil and had at least 1 evaluable omecamtiv mecarbil PK parameter.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="21.6"/>
                    <measurement group_id="O2" value="79.5" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" spread="71.2"/>
                    <measurement group_id="O2" value="259" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
        <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
          <group group_id="O2">
            <title>Group B: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
          <population>PK analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.5" upper_limit="8.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
        <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
        <population>The PK analysis set with available AUC data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
          <group group_id="O2">
            <title>Group B: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1</title>
          <population>The PK analysis set with available AUC data at each time point</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687" spread="210"/>
                    <measurement group_id="O2" value="677" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2570" spread="739"/>
                    <measurement group_id="O2" value="2670" spread="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration</title>
        <time_frame>Day 8 predose</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
          <group group_id="O2">
            <title>Group B: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration</title>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="58.5"/>
                    <measurement group_id="O2" value="192" spread="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 1: Accumulation Ratio</title>
        <description>Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)</description>
        <time_frame>Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
        <population>The PK analysis set with available AUC data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
          <group group_id="O2">
            <title>Group B: Omecamtiv Mecarbil 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 1: Accumulation Ratio</title>
          <description>Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)</description>
          <population>The PK analysis set with available AUC data at both time points</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="0.89"/>
                    <measurement group_id="O2" value="3.79" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
        <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
        <population>Pharmacokinetic analysis set with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
          <population>Pharmacokinetic analysis set with available data at each time point</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="27.2"/>
                    <measurement group_id="O2" value="107" spread="30.4"/>
                    <measurement group_id="O3" value="84.9" spread="30.0"/>
                    <measurement group_id="O4" value="154" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335" spread="32.0"/>
                    <measurement group_id="O2" value="341" spread="48.8"/>
                    <measurement group_id="O3" value="311" spread="54.2"/>
                    <measurement group_id="O4" value="537" spread="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
        <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.</time_frame>
        <population>Pharmacokinetic analysis set with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
          <population>Pharmacokinetic analysis set with available data at each time point</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="11"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.5" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.0" upper_limit="11"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
        <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
        <population>Pharmacokinetic analysis set with available AUC data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2</title>
          <population>Pharmacokinetic analysis set with available AUC data at each time point</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose on day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="902" spread="220"/>
                    <measurement group_id="O2" value="950" spread="228"/>
                    <measurement group_id="O3" value="841" spread="403"/>
                    <measurement group_id="O4" value="1330" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose on day 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3520" spread="505"/>
                    <measurement group_id="O2" value="3500" spread="519"/>
                    <measurement group_id="O3" value="3290" spread="662"/>
                    <measurement group_id="O4" value="5490" spread="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration</title>
        <time_frame>Day 27 predose</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration</title>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271" spread="44.8"/>
                    <measurement group_id="O2" value="256" spread="42.1"/>
                    <measurement group_id="O3" value="245" spread="43.3"/>
                    <measurement group_id="O4" value="401" spread="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosing Period 2: Accumulation Ratio</title>
        <description>Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).</description>
        <time_frame>Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.</time_frame>
        <population>Pharmacokinetic analysis set with available AUC data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period 2: Accumulation Ratio</title>
          <description>Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).</description>
          <population>Pharmacokinetic analysis set with available AUC data at both time points</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="1.28"/>
                    <measurement group_id="O2" value="3.81" spread="0.83"/>
                    <measurement group_id="O3" value="4.53" spread="1.19"/>
                    <measurement group_id="O4" value="4.11" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events</title>
        <description>An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment.&#xD;
A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:&#xD;
fatal&#xD;
life threatening&#xD;
required in patient hospitalization or prolongation of existing hospitalization&#xD;
resulted in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
        <time_frame>35 days</time_frame>
        <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events</title>
          <description>An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment.&#xD;
A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:&#xD;
fatal&#xD;
life threatening&#xD;
required in patient hospitalization or prolongation of existing hospitalization&#xD;
resulted in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
          <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Laboratory Toxicities</title>
        <description>Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline:&#xD;
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.&#xD;
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL).&#xD;
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.&#xD;
Grade 4: Life-threatening consequences; urgent intervention indicated.&#xD;
Grade 5: Death related to AE.</description>
        <time_frame>35 days</time_frame>
        <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Laboratory Toxicities</title>
          <description>Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline:&#xD;
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.&#xD;
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL).&#xD;
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.&#xD;
Grade 4: Life-threatening consequences; urgent intervention indicated.&#xD;
Grade 5: Death related to AE.</description>
          <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1</title>
        <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG).&#xD;
Maximum increase from Period 1 baseline was categorized as:&#xD;
≤ 30 milliseconds (ms) &gt; 30 to 60 ms &gt; 60 ms</description>
        <time_frame>Day 1 predose and day 8</time_frame>
        <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1</title>
          <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG).&#xD;
Maximum increase from Period 1 baseline was categorized as:&#xD;
≤ 30 milliseconds (ms) &gt; 30 to 60 ms &gt; 60 ms</description>
          <population>All randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 30 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 30 to 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2</title>
        <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG.&#xD;
Maximum increase from Period 2 baseline was categorized as:&#xD;
≤ 30 ms &gt; 30 to 60 ms &gt; 60 ms</description>
        <time_frame>Day 20 predose and Day 27</time_frame>
        <population>Randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo), with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).</description>
          </group>
          <group group_id="O2">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O4">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 25 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
          <group group_id="O5">
            <title>Group B: Omecamtiv Mecarbil 25 mg / 50 mg</title>
            <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2</title>
          <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG.&#xD;
Maximum increase from Period 2 baseline was categorized as:&#xD;
≤ 30 ms &gt; 30 to 60 ms &gt; 60 ms</description>
          <population>Randomized participants who received at least one dose of study treatment (omecamtiv mecarbil or placebo), with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≤ 30 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 30 to 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Period 1: Day 1 to day 19 Period 2: Day 20 to day 35</time_frame>
      <desc>Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Period 1: Placebo</title>
          <description>Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8).</description>
        </group>
        <group group_id="E2">
          <title>Period 1 Group A: OM 25 mg BID</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
        </group>
        <group group_id="E3">
          <title>Period 1 Group B: OM 25 mg BID</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8).</description>
        </group>
        <group group_id="E4">
          <title>Period 2: Placebo</title>
          <description>Participants received placebo tablets BID in dosing period 2 (days 20 to 27).</description>
        </group>
        <group group_id="E5">
          <title>Period 2 Group A: OM 25 mg BID</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
        <group group_id="E6">
          <title>Period 2 Group A: OM 37.5 mg BID</title>
          <description>Participants received omecamtiv mecarbil 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
        <group group_id="E7">
          <title>Period 2 Group B: OM 25 mg BID</title>
          <description>Participants received omecamtiv mecarbil 25 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
        <group group_id="E8">
          <title>Period 2 Group B: OM 50 mg BID</title>
          <description>Participants received omecamtiv mecarbil 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 omecamtiv mecarbil Cpredose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site nerve damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

